Market closed
Pharvaris/$PHVS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Pharvaris
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
Ticker
$PHVS
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
92
Website
Pharvaris Metrics
BasicAdvanced
$998M
Market cap
-
P/E ratio
-$2.70
EPS
-3.17
Beta
-
Dividend rate
Price and volume
Market cap
$998M
Beta
-3.17
52-week high
$33.00
52-week low
$15.37
Average daily volume
89K
Financial strength
Current ratio
19.075
Quick ratio
18.809
Long term debt to equity
0.006
Total debt to equity
0.039
Management effectiveness
Return on assets (TTM)
-33.10%
Return on equity (TTM)
-58.77%
Valuation
Price to book
3.36
Price to tangible book (TTM)
3.36
Price to free cash flow (TTM)
-8.246
Growth
Earnings per share change (TTM)
-14.36%
3-year earnings per share growth (CAGR)
13.52%
What the Analysts think about Pharvaris
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Pharvaris stock.
Pharvaris Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Pharvaris Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Pharvaris News
AllArticlesVideos
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
GlobeNewsWire·1 month ago
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference
GlobeNewsWire·1 month ago
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Pharvaris stock?
Pharvaris (PHVS) has a market cap of $998M as of December 15, 2024.
What is the P/E ratio for Pharvaris stock?
The price to earnings (P/E) ratio for Pharvaris (PHVS) stock is 0 as of December 15, 2024.
Does Pharvaris stock pay dividends?
No, Pharvaris (PHVS) stock does not pay dividends to its shareholders as of December 15, 2024.
When is the next Pharvaris dividend payment date?
Pharvaris (PHVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Pharvaris?
Pharvaris (PHVS) has a beta rating of -3.17. This means that it has an inverse relation to market volatility.